Stable crystal of 4-oxoquinoline compound

Details Stable crystal of 4-oxoquinoline compound Stable crystal of 4-oxoquinoline compound

2005-05-20

2009-12-22

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S300000, C546S123000, C546S156000

Reexamination Certificate

active

07635704

ABSTRACT:
Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractmetry.

REFERENCES:
patent: 3472859 (1969-10-01), Lesher
patent: 5519016 (1996-05-01), Kimura et al.
patent: 5688791 (1997-11-01), Kimura et al.
patent: 5985894 (1999-11-01), Clemence et al.
patent: 6034086 (2000-03-01), Kimura et al.
patent: 6248736 (2001-06-01), Turner et al.
patent: 6248738 (2001-06-01), Dickinson et al.
patent: 6248739 (2001-06-01), Turner et al.
patent: 6559145 (2003-05-01), Ciske et al.
patent: 6627646 (2003-09-01), Bakale et al.
patent: 6670377 (2003-12-01), Mekouar et al.
patent: 2002/0103220 (2002-08-01), Schnute
patent: 2003/0138483 (2003-07-01), Petriconi et al.
patent: 2004/0127708 (2004-07-01), Fuji et al.
patent: 2005/0239819 (2005-10-01), Satoh et al.
patent: 2005/0288326 (2005-12-01), Matsuzaki et al.
patent: 2006/0019906 (2006-01-01), Satoh et al.
patent: 498721 (1992-08-01), None
patent: 1140851 (2001-10-01), None
patent: 1375486 (2004-01-01), None
patent: 1 564 210 (2005-08-01), None
patent: A 48 26 772 (1973-04-01), None
patent: A 43 60 872 (1992-12-01), None
patent: 6-116241 (1994-04-01), None
patent: 6-199835 (1994-07-01), None
patent: 6-271568 (1994-09-01), None
patent: 8-183775 (1996-07-01), None
patent: 10-316570 (1998-12-01), None
patent: 2002-293745 (2002-10-01), None
patent: A 2002-534416 (2002-10-01), None
patent: A 2002-534417 (2002-10-01), None
patent: 3567162 (2004-09-01), None
patent: WO 97/38999 (1997-10-01), None
patent: WO 98/45269 (1998-10-01), None
patent: WO 00/01714 (2000-01-01), None
patent: WO 00/40561 (2000-07-01), None
patent: WO 00/40563 (2000-07-01), None
patent: WO 01/98275 (2001-12-01), None
patent: WO 02/04444 (2002-01-01), None
patent: WO 02/36734 (2002-05-01), None
patent: WO 02/055079 (2002-07-01), None
patent: WO 02/070486 (2002-09-01), None
patent: WO 03/010147 (2003-02-01), None
Muzaffar et al. “Polymorphism and drug availability” J. Phar. 1(1) 59-66 (1979).
Jain et al. “Polymorphisom in pharmacey” Indian Drugs 23(g)315-329 (1986).
Doelker et al. “Crystalline modification . . . ” CA 138:209993 (2002).
Doelker et al. “Physicochemical behavior or active . . . ” CA 132:325872 (2000).
Otsuka et al. “effect of polymorphic . . . ” Chem. Pharm. Bull, 47(6) 852-856 (1999).
Brittain “Polymorphism in pharmaceutical solids” Marcel Dekker inc. p. 2, (1999).
US Pharmacopia #23 national formulary #18, p. 1843-1844 (1995).
Wikipedia “Polymorphosm” free encyclopedia (2006).
Engleson “Concise encyclopedia Chemistry” p. 872-873 (1993).
Sleasman et al. “HIV-1 infection” CA 139:305926 (2003).
Parienti “Cytokine therapy or structured treatment . . . ” CA 137:92237 (2002).
Goho “Tricky business” Science News online, (Aug. 2004) p. 1-9.
Knapman “polymorph prediction” The Alchemist (Oct. 1999) 1/2, p. 1-3, 2/2, p. 1-3.
Brittain “polymorphism . . . ” p. 57-58 (1999).
Bernstein “Polymorphism . . . ” p. 108 (2002).
Ulrich Crystallization{ Kirk-Othmer encyclopedia of chem. tech. p. 95-147 (2002).
CMU Pharmaceutical polymorphism, internat p. 1-3 (2002) (print out Apr. 3, 2008).
Singhal et al. “Drug polymorphism . . . ” Advanced drug delivery reviews 56. p. 335-347 (2004).
Lanz et al. “Pharmaceutical powder technology . . . ” (2006) p. 110.
Marsac et al. “Sppontaneous crystallinity loss . . . ” J. Pharm Sci. v. 97(8) p. 3182-3194 (2008).
Elbary et al. “Polymorphic transformation . . . ” CA 136:58666 (2001).
Nair et al. “Influence of polyethylene glycol and povidone . . . ” CA 138:260244 (2002).
Henck et al. “Designing a molecular . . . ” Drug. disclovery Today v. 12(5/6) p. 189-199 (2007).
Niazi “handbook of pharmaceutical manufacturing . . . ” p. 1( form internet ) (2004).
Cushman et al. “Cosalane analogues . . . ” J. Med. Chem. v.38, p. 443-52 (1995).
Abdul-Ahad,Europ. J. of Med. Chem, 17(4), pp. 301-306 (1982).
Baker,J. Med. Chem, 15(3), pp. 235-237 (1972).
Chou and Talalay, Adv. Enzyme Regul. 22:27-55 (1984).
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescent, pp. i-iii and 1-111, (Aug. 13, 2001).
Hirao, I. et al.,Studies on the Synthesis of Quinoline Compounds, I. Memoirs Kyushu Inst. Tech. (Eng.), 14:13-16 (1984).
Hirao, I. et al.,Antibacterial Activities of Oxodihydroquinoline Carboxylic Acid Derivatives, Memoirs Department of Engineering, 14:21-32 (1990).
Mol. Pharmacol. 10:235-247 (1974).
Stefancich, Farmaco, Edizioje Scientific, 42(1), pp. 3-16 (1987).
Vincent, K.A., et al.,Characterization of Human Immunodeficiency Virus Type I Integrase Expressed In Eschericia coli and Analysis of Variants with Amino-Terminal Mutations, J. Virol. 67: 425-437 (1993).
Walton,Antimicrobial Agents, Chemotherapy, 32(7) pp. 10869 (1988).
Yoshimoto,J. Med. Chem, 19(1), pp. 71-98 (1976).
PCT International Search Report (PCT/JP2005/009604) dated Nov. Oct. 28, 2005.

Affiliated with

Also associated with

Rating

Stable crystal of 4-oxoquinoline compound does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stable crystal of 4-oxoquinoline compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable crystal of 4-oxoquinoline compound will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4108168